---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-037486"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:25:00.641629+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Stoke reports positive interim Phase 1/2a data for STK-001 in Dravet syndrome; 55% median seizure reduction at 45mg

## Summary
- STK-001 up to 45mg well-tolerated; 55% median reduction in convulsive seizures with three doses of 45mg (n=6).
- 74% of patients (20/27) experienced reduction in seizure frequency after three doses of STK-001.
- Cash of $252.2M as of Sep 30, 2022 expected to fund operations into 2025; Q3 net loss $26.1M ($0.66/share).
- FDA granted Rare Pediatric Disease Designation for STK-001 in Dravet syndrome in October 2022.
- Planned data updates on multiple doses of 45mg and 70mg in 2023; AES presentation Dec 2-6.

## SEC filing metadata
- accession: 0001564590-22-037486
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000156459022037486/0001564590-22-037486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000156459022037486/stok-8k_20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-037486
- JSON: https://secwatch.observer/filing/0001564590-22-037486.json
- Plain text: https://secwatch.observer/filing/0001564590-22-037486.txt

## Key facts
- Earnings Releases
  Stoke Therapeutics, Inc. reported financial results for the third quarter of 2022.
  - Period: the third quarter of 2022
  - Result: reported results
  source text: Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of 2022 and provided business updates, including positive data from a planned interim analysis of the ongoing Phase 1/2a MONARCH and ADMIRAL clinical studies of STK-001 in children and adolescents with Dravet syndrome.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000156459022037486/0001564590-22-037486-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.